It answers a decision, not a research question
This is scoped around what you have to decide and when, rather than around what would be publishable. Both are legitimate; only one of them is this offering.
Offering 3 of 5
The answer to a business question, in a form you can act on.
A designed analysis run against de-identified patient-level data, in-market, under that market's own law. Treatment pathways, market dynamics, unmet need, patient flow, adherence, switching, or whatever the question requires. Delivered as a report or an interactive dashboard, with the method note behind it.
Analysis & Insight
Why this is the offering most teams use most
It is fast enough to be useful
A protocol-driven study is the right instrument when the output has to be defended externally. When it has to inform a decision in six weeks, this is the right one.
The method is documented anyway
You get the method note whether or not you asked for it, which means the analysis can be defended later or extended into a full study without redoing the design.
A dashboard makes it repeatable
Where the question will be asked again, the output can be delivered as a view your team refreshes rather than a document that goes stale.
3
Analysis & Insight
A designed analysis run against de-identified patient-level data, in-market, under that market's own law.
- Timeline
- Six to twelve weeks where access is established. Approvals, not analysis, set the number.
- Buy it when
- You need to make a commercial or medical decision and you need it grounded in what actually happened rather than in a model or an assumption.
- Do not buy it when
- The output will be submitted to a regulator or an HTA body, or published. That needs the protocol discipline of offering four.
Deliverables
What you actually receive.
Named, dated and agreed at scoping. Every one of these is a thing you can hold, circulate internally and be held to, not a description of an activity.
An analysis report
The finding, the figures behind it, and what it means for the decision you are making. Written for the audience you name at scoping, not a single generic template.
A signed method note
Cohort definition, analytical approach, handling of missing data and confounders, and the limitations. This is what makes the result defensible six months later.
Result tables
The underlying tabulations, exportable, so your own team can check or re-cut anything.
An interactive dashboard, where it fits
For questions that will be asked repeatedly, delivered as a maintained view rather than a document.
An interim read
You see the direction before you see the deck. There are no surprises at the final presentation.
A findings walkthrough
A working session with the person who did the analysis, not a handover to an account manager.
How it runs
Four steps, and you see the direction before you see the deck.
Specification
The cohort specification is agreed and dated. If feasibility came first, this is already done.
Execution in-market
Credentialed analysts run the analysis inside the alliance partner's controlled-access environment. The data does not move.
Interim read
A first look at the direction, so the interpretation can be shaped while there is still time to ask a second question.
Final delivery
Report or dashboard, method note, result tables, and a session to go through it.
Alongside every engagement: weekly updates, methodology agreed before work starts, quality control at every phase, interim reporting rather than a single reveal, and milestones you accept rather than discover.
What it feeds into
Real-World Evidence Study
The method note becomes the protocol skeleton for a study designed to be defended in front of somebody else.
Is this the one you need?
Describe the decision you are trying to make. If a cheaper offering answers it, we will tell you that instead.